Genelux reports 16.7-month PFS in phase 1b/2 Olvi-Vec trial case study for platinum-relapsed SCLC
GNLX•Ongoing trial enrollment and next updates
Enrollment continues in systemic Olvi-Vec lung cancer trials; additional dose-finding updates are expected later in 2026.
Peer-reviewed case report from OLVI-VEC-202-SCLC
Genelux flagged a peer-reviewed case report from its OLVI-VEC-202-SCLC study in platinum-relapsed small cell lung cancer.
Results were previously reported in part, then published in Frontiers in Oncology on Sept. 9, 2026.
Patient outcome after intravenous Olvi-Vec and platinum re-challenge
The patient showed a deep, durable tumor response following intravenous Olvi-Vec, then platinum chemotherapy re-challenge.
Outcome exceeded the patient’s earlier first-line platinum-based treatment, supporting Olvi-Vec’s potential to restore chemotherapy sensitivity.
